Study on Oxytocin and Mindfulness Training for Reducing Stress in Adults with Psychological Distress

1 1 1

What is this study about?

This clinical trial is focused on understanding how the combination of the hormone oxytocin and mindfulness training can help reduce stress in adults experiencing psychological distress. Psychological distress refers to feelings of anxiety, depression, or stress that can affect daily life. The study will use a nasal spray containing oxytocin, a naturally occurring hormone known for its role in social bonding and stress regulation.

The purpose of the study is to see if using oxytocin together with mindfulness training is more effective in managing stress than using either approach alone. Mindfulness training involves exercises that help individuals focus on the present moment, which can improve emotional well-being. Participants will receive either the oxytocin nasal spray or a placebo during mindfulness sessions to compare the effects on stress levels.

Throughout the study, participants will be asked to complete various questionnaires to assess their levels of stress, mood, and quality of life. These assessments will help researchers understand the impact of the treatment on psychological distress. The study aims to provide insights into how combining oxytocin with mindfulness training might enhance stress management in individuals with heightened stress complaints.

1 initial assessment

Participants will undergo an initial assessment to evaluate their current level of psychological distress. This will involve completing self-report questionnaires such as the Perceived Stress Scale (PSS) and the Depression Anxiety Stress Scale (DASS-21).

2 oxytocin administration

Participants will receive oxytocin through a nasal spray. The product used is Oxytocine CD Pharma 40 IE/ml nasal spray, solution. The administration is intranasal, meaning it is delivered through the nose.

3 mindfulness training sessions

Participants will engage in mindfulness-based training sessions. These sessions are designed to help manage stress and improve emotional well-being.

4 combined treatment evaluation

The study aims to evaluate the effects of combining oxytocin administration with mindfulness training. This will be compared to the effects of each intervention when administered alone.

5 follow-up assessments

Participants will complete follow-up assessments to measure changes in stress levels and emotional well-being. This will include repeating the initial self-report questionnaires and additional assessments such as the State Adult Attachment Measure (SAAM) and the Self-Compassion Scale-Short Form (SCS-SF).

Who Can Join the Study?

  • The participant must give their voluntary written informed consent before any screening procedures. This means they agree to join the study after understanding what it involves.
  • The participant must be between 18 and 50 years old when they sign the Informed Consent Form.
  • The participant must report experiencing mild to severe stress symptoms. This is measured using a tool called the DASS-21, which checks stress levels. Scores between 15-25 indicate mild to moderate stress, and scores of 26 or higher indicate severe to extremely severe stress.
  • The participant must be able to understand and use the Dutch language well enough to complete study tasks, but they do not need to be native speakers.

Who Cannot Join the Study?

  • Individuals with severe psychological distress complaints, which means experiencing intense emotional discomfort or stress.
  • Participants who are not within the age range specified for the study.
  • Individuals who are part of a vulnerable population, meaning those who might need special protection or care.
  • Participants who do not meet the specific health or medical conditions required for the study.
  • Individuals who are not able to follow the study procedures or instructions.
  • Participants who are currently involved in another clinical trial.
  • Individuals with any medical condition that the study team believes could interfere with the study results.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Kx Liyhiq Leuven Belgium

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Recruiting
01.03.2025

Trial locations

Investigated drugs:

Oxytocin is a hormone that plays a role in social bonding, stress regulation, and emotional responses. In this clinical trial, oxytocin is administered to participants to see if it can help reduce stress when combined with mindfulness training. The goal is to determine if this combination is more effective in managing stress than using either oxytocin or mindfulness training alone.

Mindfulness Training involves practices that help individuals focus on the present moment, often through meditation and breathing exercises. This training aims to improve mental well-being and reduce stress by encouraging participants to be more aware of their thoughts and feelings without judgment. In this trial, mindfulness training is paired with oxytocin administration to assess its effectiveness in enhancing stress regulation.

Psychological Distress – Psychological distress refers to a state of emotional suffering characterized by symptoms such as anxiety, depression, and stress. It often arises in response to challenging life events or situations and can affect a person’s ability to function in daily life. Individuals experiencing psychological distress may feel overwhelmed, have difficulty concentrating, and experience changes in sleep or appetite. The condition can vary in intensity and duration, with some people experiencing temporary distress while others may face more persistent symptoms. Psychological distress is not a specific mental disorder but rather a general term that encompasses a range of emotional and psychological challenges. It is important to recognize and address these feelings to prevent them from impacting overall well-being.

Trial ID:
2024-513482-39-00
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study of psilocybin therapy for psychological distress in patients with COPD, ALS, multiple sclerosis, or atypical Parkinson’s disorders

    Recruiting

    1 1
    Investigated drugs:
    Czechia Denmark The Netherlands Portugal
  • A Study of Oxytocin Nasal Spray to Reduce Psychological Stress in Women Who Have Recovered from Breast Cancer

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium